A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients
Recruiting now
Conditions studied: Breast Cancer
In brief
The purpose of this study is to evaluate ethanol-induced symptoms and safety in breast cancer patients with neoadjuvant/adjuvant chemotherapy including Non-ethanol formulation docetaxel before and after surgery
Key facts
- Study ID
- NCT06537752
- Run by
- Boryung Pharmaceutical Co., Ltd
- People needed
- 1052
- Starts
- 2024-07-15
- Expected to finish
- 2026-10-01
- Last updated by the study team
- 2025-09-12
Who can join
Age: 19 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Those who voluntarily signed a written personal information collection and usage agreement after receiving an explanation about the objective and method, etc. of this clinical study.
- Those are confirmed to have primary breast cancers through histological diagnosis and one of the following are applicable.
- Those who need neoadjuvant chemotherapy as breast cancer patients
- Those who need adjuvant chemotherapy after breast cancer surgery
- Those who are scheduled to administer non-ethanol formulation docetaxel according to chemotherapy
- Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.
You may not qualify if…
- Those are diagnosed with other primary cancer that can influence the treatment or prognosis of primary breast cancers.
- Those are diagnosed with secondary breast cancers.
- Those with Stage 0/1 (Tis, N0, M0) or Stage IV (any T, Any N, M1) breast cancers.
Where it is running
- Chung-Ang University Hospital — Seoul, South Korea (enrolling)
- Uijeongbu Eulji Medical Center, Eulji University — Uijeongbu-si, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.